Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) was the recipient of a significant drop in short interest in September. As of September 15th, there was short interest totalling 1,734,180 shares, a drop of 28.4% from the August 31st total of 2,422,384 shares. Based on an average daily volume of 253,202 shares, the days-to-cover ratio is currently 6.8 days. Approximately 4.0% of the shares of the stock are sold short.

Several research firms recently issued reports on PIRS. HC Wainwright set a $9.00 target price on Pieris Pharmaceuticals and gave the stock a “buy” rating in a research report on Monday. BidaskClub cut Pieris Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 26th. Finally, TheStreet cut Pieris Pharmaceuticals from a “c-” rating to a “d-” rating in a research report on Monday, June 12th. Four research analysts have rated the stock with a buy rating, The company presently has a consensus rating of “Buy” and a consensus target price of $9.00.

In other Pieris Pharmaceuticals news, insider Allan Reine bought 65,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The stock was purchased at an average price of $4.82 per share, for a total transaction of $313,300.00. Following the completion of the transaction, the insider now owns 45,000 shares of the company’s stock, valued at approximately $216,900. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director James A. Geraghty bought 10,000 shares of the business’s stock in a transaction that occurred on Thursday, August 17th. The shares were acquired at an average price of $4.82 per share, with a total value of $48,200.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $48,200. The disclosure for this purchase can be found here. Company insiders own 4.05% of the company’s stock.

Several institutional investors have recently made changes to their positions in the business. Creative Planning raised its holdings in shares of Pieris Pharmaceuticals by 8.3% during the second quarter. Creative Planning now owns 65,000 shares of the biotechnology company’s stock valued at $329,000 after acquiring an additional 5,000 shares during the last quarter. Voya Investment Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at approximately $100,000. State of Wisconsin Investment Board acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at approximately $132,000. The Manufacturers Life Insurance Company raised its holdings in shares of Pieris Pharmaceuticals by 1,106.3% during the second quarter. The Manufacturers Life Insurance Company now owns 31,785 shares of the biotechnology company’s stock valued at $161,000 after acquiring an additional 29,150 shares during the last quarter. Finally, Acadian Asset Management LLC acquired a new position in shares of Pieris Pharmaceuticals during the second quarter valued at approximately $162,000. 50.50% of the stock is owned by institutional investors and hedge funds.

Pieris Pharmaceuticals (NASDAQ:PIRS) opened at 6.34 on Thursday. The stock’s market cap is $280.91 million. The firm’s 50-day moving average price is $5.55 and its 200 day moving average price is $5.55. Pieris Pharmaceuticals has a 12-month low of $1.30 and a 12-month high of $6.48.

COPYRIGHT VIOLATION WARNING: “Short Interest in Pieris Pharmaceuticals, Inc. (PIRS) Declines By 28.4%” was posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this piece of content on another publication, it was copied illegally and republished in violation of US and international trademark and copyright laws. The legal version of this piece of content can be viewed at https://www.thecerbatgem.com/2017/10/05/short-interest-in-pieris-pharmaceuticals-inc-pirs-declines-by-28-4.html.

Pieris Pharmaceuticals Company Profile

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Receive News & Stock Ratings for Pieris Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.